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Diagnostic algorithmThe neuronal ceroid lipofuscinoses (NCLs) are lysosomal storage disorders and together are the most common
degenerative brain diseases in childhood. They are a group of disorders linked by the characteristic accumulation
of abnormal storage material in neurons and other cell types, and a degenerative disease course. All NCLs are
characterized by a combination of dementia, epilepsy, andmotor decline. Formost childhoodNCLs, a progressive
visual failure is also a core feature. The characteristics of these symptoms can vary and the age at disease onset
ranges from birth to young adulthood. Genetic heterogeneity, with fourteen identiﬁed NCL genes and wide phe-
notypic variability render diagnosis difﬁcult. A new NCL classiﬁcation system based on the affected gene and the
age at disease onset allows a precise and practical delineation of an individual patient's NCL type. A diagnostic
algorithm to identify each NCL form is presented here. Precise NCL diagnosis is essential not only for genetic
counseling, but also for the optimal delivery of care and information sharingwith the family and other caregivers.
These aspects are challenging because there are also potential long term complications which are speciﬁc to NCL
type. Therefore care supported by a speciﬁcally experienced team of clinicians is recommended. As the underly-
ing pathophysiological mechanism is still unclear for all NCL forms, the development of curative therapies re-
mains difﬁcult. This article is part of a Special Issue entitled: The neuronal ceroid lipofuscinoses or Batten
Disease.
© 2013 Published by Elsevier B.V.1. Introduction and deﬁnition
Diagnosis of childhood dementia represents a huge challenge. The
neuronal ceroid lipofuscinoses (NCLs) are the most common cause of
dementia in children. They are a group of diverse disorders linked
by the characteristic accumulation of abnormal storage material in
neurons and other cell types, and a degenerative disease course. They
form a heterogeneous group of incurable lysosomal storage diseases
which lead to dementia, epilepsy, blindness (usually) andmotor deteri-
oration [1,2]. The number of different NCL causing genes is high with
signiﬁcant variability within and across forms.
The authors of this article, clinicians with particular interest and
experience of the NCLs, want to show that it is possible to diagnose
NCL disease in an economical manner and give hints for the manage-
ment of disease-speciﬁc problems.ronal Ceroid Lipofuscinoses or
: +44 207 188 4629.
lliams@doctors.org.uk
sevier B.V.2. New nomenclature of NCL diseases
Traditionally, NCL diseases were classiﬁed according to the age at
disease onset (congenital, infantile, late infantile, juvenile, adult) and
sometimes also according to the respective authors (Haltia-Santavuori,
Jansky-Bielschowsky, Batten, Spielmeyer-Vogt, Kufs) [2].
NCL diseases are however much more genetically heterogeneous
than initially thought. Mutations in the same gene may also lead to
very different disease courses [3,4]. Other designations such as “Finnish”
or “Turkish” NCL variant are outdated, as mutations in the respective
genes in fact occur worldwide [5]. Therefore, the hitherto existing
nomenclature is obsolete.
An internationally developed new NCL nomenclature clearly iden-
tiﬁes each NCL disease both genetically and clinically (Table 1) [2,6]:
it classiﬁes both the defective gene as well as the age at disease onset
(congenital, infantile, late infantile, juvenile or adult). An exact diagno-
sis is essential for genetic counseling, sharing information regarding
prognosis and future disease course, and for optimal symptom care.
3. The genetic spectrum of NCL diseases
To date, fourteen different NCL forms have been described (Table 1)
[3,7–13]. More NCL genes remain to be identiﬁed as in some patients
mutations cannot be demonstrated in any of the known NCL genes
Table 1
Genetic spectrum and new nomenclature of NCL diseases.
Disease MIM number/reference Gene Protein
CLN1 disease, infantile
CLN1 disease, late-infantile
CLN1 disease, juvenile
CLN1 disease, adult
#256730 CLN1/PPT1 PPT1a
CLN2 disease, late-infantile
CLN2 disease, juvenile
#204500 CLN2/TPP1 TPP1a
CLN3 disease, juvenile #204200 CLN3 Transmembrane protein
CLN4 disease, adult (AD inheritance) #162350 CLN4/DNAJC5 Soluble cysteine string protein α
CLN5 disease, late-infantile
CLN5 disease, juvenile
CLN5 disease, adult
#256731 CLN5 Soluble lysosomal protein
CLN6 disease, late-infantile
CLN6 disease, adult (Kufs type A)
#601780 CLN6 Transmembrane protein
CLN7 disease, late-infantile #610951 CLN7/MFSD8 Transmembrane protein
CLN8 disease, late-infantile
CLN8 disease, EPMR
#600143 CLN8 Transmembrane protein
CLN10 disease, congenital
CLN10 disease, late-infantile
CLN10 disease, juvenile
CLN10 disease, adult
#610127 CLN10/CTSD Cathepsin Da
CLN11 disease, adult [9] CLN11/GRN Progranulinb
CLN12 disease, juvenile [10] CLN12/ATP13A2 ATPase type 13A2c
CLN13 disease, adult (Kufs type B) [13] CLN13/CTSF Cathepsin Fa
CLN14 disease, infantile [12] CLN14/KCTD7 Potassium channel tetramerization domain
containing protein type 7d
a Lysosomal enzymes.
b GRN mutations also in Frontotemporal lobar degeneration with TDP43 inclusions MIM #607485.
c ATP13A2 mutations also in Kufor–Rakeb syndrome (KRS, Parkinson disease 9) MIM #606693.
d KCTD7 mutations also seen in progressive myoclonic epilepsy type 3 (EPM3) MIM #611726.
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tic lysosomal storage material.
Intracellular localisation and function (where known) of the defec-
tive NCL proteins are different: four NCL types are caused by defects in
lysosomal enzymes (CLN1, CLN2, CLN10, CLN13), others by defects in
transmembrane proteins (CLN3, CLN6, CLN7, CLN8) [7]. Mutations in
an ATPase gene (CLN12) [10] and a potassium channel gene (CLN14)
[12] also cause NCL disease. The recently identiﬁed CLN4 gene
(DNAJC5) codes for a protein with putative function in synapses [8].
How these genetic defects lead to neurodegeneration is still not
understood.
Clinically, the different NCL diseases have much in common despite
their heterogeneity. This is important both for diagnosis and (palliative)
treatment. To date, there is no disease-modifying or curative treatment
for any of the NCLs.
4. The clinical spectrum of NCL diseases
In almost all NCL forms the patients are initially healthy and have
a normal developmental proﬁle. The main alerting symptoms are the
combination of two or more of dementia, visual loss, epilepsy, and
motor deterioration. The age at disease onset can range from birth
to adulthood. The order in which symptoms occur is variable and
depends both on age at onset and on genetic form. In a young child,
ﬁrst symptoms are developmental slowing followed by standstill, then
later regression of psychomotor development, or epilepsy. In a school
child, ﬁrst symptoms are usually visual loss and behavior change,
followed by dementia [2]. The different disease courses are described
as follows [2]:
4.1. Congenital onset NCL
Congenital CLN10 disease is the only NCL form where patients are
already severely affected at birth. Intrauterine or immediate postnatal
onset of epileptic seizures as well as congenital microcephaly should
lead to the suspected diagnosis. The disease leads to death in early
infancy. It is associated with the deﬁciency of the lysosomal enzymecathepsin D. Conﬁrmation of the diagnosis is based on demonstration
of the enzymatic deﬁciency and a mutation in the CLN10 gene [14].
4.2. Infantile onset NCL
4.2.1. CLN1 disease
In patients with this NCL form [15], early development appears
normal until 6–18 months of age. At onset, there is typically decreased
tone and decreased social interaction followed by rapidly progressive
psychomotor regression, myoclonus, seizures, and visual failure. By
2 years of age, there is blindness with optic atrophy and macular and
retinal changes but no pigment aggregation. Fulminant brain atrophy
leads to progressive microcephaly. The electroencephalogram becomes
ﬂat. There is also early extinction on the electroretinogram. Seizures in
infantile NCLmay not be as prominent as in later-onset forms. Ultimate-
ly, spasticity develops and patients become vegetative [16]. The disease
is associated with the deﬁciency of the lysosomal enzyme palmitoyl
protein thioesterase 1 (PPT1) and is caused bymutations in CLN1. Diag-
nosis is based on the enzyme deﬁciency and mutation of the gene.
4.2.2. CLN14 disease
Two infant siblings have been reportedwhopresentedwithmyoclo-
nus, developmental regression and visual failure. A mutation in KCTD7,
a gene responsible for the function of a potassium channel, was found
[12].
4.3. Late-infantile onset NCL
The classic late infantile onset NCL is caused by mutations in CLN2,
but many other forms also present between ages 1 and 4 years.
4.3.1. CLN2 disease
Patients with this classic late infantile NCL [17] typically present
with slowing of development and psychomotor regression, usually
in the second or third year of life. Epilepsy typically develops between
2 and 4 years of age. Epilepsy takes many forms in this NCL form and
is often refractory to medical treatment. Vision loss is associated with
Fig. 1. Fundoscopic appearance of the retina of a patient with juvenile CLN3 disease.
Irregular pigment distribution and thin blood vessels are visible.
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tion is most visible in the macula. The general decay of psychomotor
functions is rapid and uniform between the third and ﬁfth birthday
[18]. Children with later onset (after 4 years) tend to have milder
course with more prominent ataxia and less prominent epilepsy.
The disease is associated with the deﬁciency of the lysosomal enzyme
tripeptidyl peptidase 1 (TPP1) and is caused by mutations in CLN2,
the demonstration of both of which serves for diagnosis.
4.3.2. CLN1 disease
CLN1 disease is characterized by visual and cognitive decline
followed by ataxia and myoclonus [19].
4.3.3. CLN5 disease
This form of late-infantile NCL [20] has been called the “Finnish
variant,” but it occurs world-wide [5]. Age at onset is more variable
than in classic CLN2 disease, a mean age at onset of 5.6 years (range
4–17 years). Clinical features include psychomotor regression, ataxia,
myoclonic epilepsy, and visual failure. Vision lossmay be the presenting
sign. Diagnosis depends on analysis of CLN5.
4.3.4. CLN6 disease
CLN6 disease [21] has a variable age at onset ranging from
18 months to 8 years. Clinical features include motor delay, dysarthria,
ataxia, vision loss, and seizures. Seizures are an early feature, starting
before age 5 years in the majority of patients. Early vision loss occurs
in about half of patients with this disease. Deterioration is rapid and
death usually occurs between 5 and 12 years of age. Diagnosis depends
on analysis of CLN6.
4.3.5. CLN7 disease
CLN7 disease [22] has also been called the “Turkish” variant but
has been shown to occur world-wide. Age at onset is 2–7 years. The
initial symptom is typically seizures followed by progressive motor
decline, myoclonus, cognitive changes, and vision loss. Diagnosis is
through gene analysis.
CLN8 disease occurs in two primary forms [23]. The late-infantile
form is characterized by vision loss, myoclonic seizures, progressive
motor and cognitive decline, and early death. Age at onset is 5–
10 years of age. CLN8mutations have also been associated with “North-
ern Epilepsy” which is a form of progressive myoclonus epilepsy but
does not have the vision loss associated with NCL [24]. Diagnosis is
through gene analysis.
4.4. Juvenile onset NCL
Classic juvenile NCL is due to mutations in the CLN3 gene, but
juvenile onset has been reported in other forms.
4.4.1. CLN3 disease
This classic juvenile NCL form [25] presents between ages 4 and
7 years with insidious onset of blindness caused by retinal degenera-
tion (Fig. 1). Progressive cognitive decline and behavioral problems
follow. The behavior problems are typically characterized as angry
outbursts, physical violence, and anxiety with features of depression.
Seizures develop slightly later. Generalized tonic–clonic seizures are
the most common in CLN3 disease, but are typically well-controlled
with medication at least initially. The movement disorder in CLN3
disease is parkinsonism, that is sometimes responsive to L-DOPA.
CLN3 disease has a severe, characteristic dysarthria that is most
prominent after 10 years of age. In addition to the neurologic features,
CLN3 patients manifest a cardiac conduction abnormality in the second
decade of life. Age at death is usually in the third decade. Diagnosis
relies on the demonstration of vacuolated lymphocytes in peripheral
blood and on mutations in CLN3, where a typical deletion is found in
the wide majority of cases.4.4.2. CLN1 disease
Juvenile-onset NCL due to CLN1 mutations [26] differs from both
CLN3 disease and classic infantile NCL [15]. Age at onset is 5–10 years
with cognitive decline as the earliest symptom in most. Seizures occur
in multiple forms. Motor decline occurs, but there is typically neither
parkinsonism normyoclonus. Spasticity and ataxia may develop. Vision
loss is late in this form, occurring usually between ages 10 and 14 years.
Diagnosis is as for the infantile form of CLN1 disease.
4.5. Adult onset NCL
Classic adult onset NCL (Kufs disease) had been categorized as
CLN4 disease, but it is now apparent that there are multiple causes
of adult-onset NCL.
4.5.1. CLN4 disease
This has recently been reclassiﬁed to refer to “Parry disease” associ-
ated with mutations in DNAJC5 [11]. This is the only autosomal domi-
nant NCL. Symptom onset occurs after age 30 years. Clinical features
include ataxia, progressive dementia, seizures, and myoclonus with no
visual loss. Diagnosis depends on mutations in CLN4 (DNAJC5).
4.5.2. CLN6 disease
The Kufs type A variant of adult-onset NCL [27] was recently associ-
ated with mutations in CLN6 [8]. This form of NCL has onset around
30 years of age with progressive myoclonic epilepsy followed by devel-
opment of dementia and ataxia. Dysarthria is prominent. There is no
vision loss in this disease. Death typically occurs within 10 years. Kufs
Type B is clinically similar, but without the epilepsy and dysarthria.
Mutations in the CLN6 gene are diagnostic.
4.5.3. CLN13 disease
The Kufs type B variant [27] presents in the same age range as type
A with dementia as well as cerebellar and/or extra-pyramidal signs.
The disease is associated with a deﬁciency of the lysosomal enzyme
cathepsin F. Mutations in the responsible gene [13] allow diagnosis.
4.5.4. CLN1 disease
Adult onset NCL due to CLN1 mutations is characterized by onset
after 18 years of age [28]. Cognitive decline and depression are the ini-
tial manifestations followed by development of ataxia, parkinsonism,
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testing of PPT1 activity and mutation analysis.
The NCLs described above have several features in common
suggesting biological similarities or functional interactions between
involved genes. The clinical manifestations of the different NLCs differ
in age at onset, order of progression, and speciﬁc symptoms. This var-
iability suggests either differential gene expression within the CNS or
differential vulnerability of different neuronal populations. Knowl-
edge of clinical presentations can help guide diagnostic evaluation
in patients with features of NCL. However, more quantitative study
of the natural history in NCLs is required to inform neurobiological
investigations and development of outcome measures for clinical
trials.
5. Strategy for the diagnosis of NCL types
The clinical approach to diagnosis of an NCL disorder starts at the
age at which symptoms appear. Suggestive situations can be divided
in four typical groups: (1) very young infants, including newborns
with congenital epilepsy and microcephaly, (2) young children withTable 2
Diagnostic algorithm for NCL diseases.
Clinical presentation Necessary diagnostic Possibly
affected genes
Newborn with epilepsy and
microcephaly
Enzyme testing for cathepsin
D (CtsD) (leucocytes of
ﬁbroblasts).
CTSD deﬁcient: CLN10
Young child (>6 months) with
developmental standstill or
regression and/or newly
occurring severe epilepsy of
unknown cause
Enzyme testing for PPT1 and
TPP1 (dry blood spots or
leucocytes or ﬁbroblasts)
PPT1 deﬁcient: CLN1
TPP1 deﬁcient: CLN2
If PPT1 and TPP1 enzyme
activities are normal: Electron
microscopic examination
(skin biopsy or lymphocytes).
If storage material is present:
genetic testing.
CLN5, CLN6, CLN7,
CLN8, CLN14
School child with visual loss
and/or dementia and epilepsy
Search for lymphocyte
vacuoles (light microscopy of
blood smear, Fig. 2).
If lymphocyte vacuoles are
present:
CLN3
If no lymphocyte vacuoles,
enzyme testing for PPT1, TPP1
and CtsD (see above)
PPT1 deﬁcient: CLN1
TPP1 deﬁcient: CLN2
CTSD deﬁcient: CLN10
If PPT1 and TPP1 enzyme
activities are normal: Electron
microscopic examination
(skin biopsy or lymphocytes).
If storage material is present: CLN5, CLN6, CLN7,
CLN8, CLN12
Young adult with non-speciﬁc
mental, motor or behavioral
abnormalities.
Enzyme testing for PPT1, TPP1
and CtsD (see above)
PPT1 deﬁcient: CLN1
TPP1 deﬁcient: CLN2
CTSD deﬁcient: CLN10
CTSF deﬁcient: CLN13
If enzyme activities are
normal: Electron microscopic
examination (skin biopsy or
lymphocytes).
If storage material is present:
genetic testing (eventually in
special cases even without
detection of storage material),
consider possible mode of
inheritance.
If autosomal
dominant: CLN4
If autosomal
recessive: CLN6,
CLN11, CLN13developmental standstill or regression and severe epilepsy, (3) school
children with visual loss, followed by dementia and epilepsy, and
(4) young adults with non-speciﬁc mental, motor or behavioral
abnormalities. In each of these groups, a characteristic set of NCL
types can be expected, caused by variable mutations in the known
NCL genes.
Table 2 provides an algorithm of diagnostic investigations once an
NCL is considered in a person with suggestive symptoms. Initial labo-
ratory studies comprise enzymatic tests, light and electron microscopic
investigations of intracellular storage that, when performed in the log-
ical order shown, lead straight and economically to adequatemolecular
genetic conﬁrmation.
6. Specialized palliative therapies in NCL
Palliative therapies in NCL diseases represent a signiﬁcant challenge
due to multiple symptom complexes and affected body systems. More-
over, treatment is difﬁcult as most patients have severe visual impair-
ment and may not be able to communicate verbally with caregivers.
Collaboration with a team of clinicians with NCL experience is
recommended in order to improve palliative medication: Table 3 is
based on experience collected by such teams and gives an overview of
medication found to be helpful in treating themost common symptoms
of NCLs.
Epilepsy in NCL is therapy-resistant in most cases. Progressive brain
degeneration leads to changes in the effectiveness of medication and to
unexpected toxicity. Therefore, the following rules should be followed
for treating seizures in NCL:
(1) Neither complete absence of seizures nor normalization of
electroencephalogram (EEG) is realistic goal of treatment.
(2) The EEG in NCL is mainly for monitoring. Therapy should be
adjusted to clinical symptoms.
(3) Therapy with more than two anticonvulsants may result in
increased side effects rather than reduction of seizures.
(4) Some anticonvulsants are recommendable for NCL patients
(valproate and lamotrigine), others may have negative effects
on the disease course and should be avoided (carbamazepine,
phenytoin, vigabatrin). See Table 3.
(5) Use only as many drugs as necessary and as few as possible.
Myoclonus is a symptom difﬁcult to treat. However, it is often
more distressing for caregivers than to the patients. Levetiracetam
and piracetam are at least partially effective treatments (Table 3).Fig. 2. Vacuoles in the cytoplasm of a peripheral blood lymphocyte from a patient with
juvenile CLN3 disease. Routine blood smear.
Table 3
Overview on medication for palliative therapies in NCL.
Symptom Substance Comment
Epilepsya Valproate Advantage: mood stabilizing effect, useful in
juvenile NCL patients with psychotic symptoms
Lamotrigine
Topiramate Increase dosage slowly tominimize side effects
such as speech disturbance (starting dose
0.5 mg/kg/d). Agitation may be a side effect. In
this case discontinue the drug.
Levetiracetame Severe agitation is a possible side effect in
juvenile NLC.
Diazepam, lorazepam Acute therapy of prolonged grandmal seizures
Myoclonus Levetiracetame Also effective as anti-epileptic medication
(especially in late infantile NCL)
Zonisamide
Piracetame High dosage required (300-350 mg/kg/d)
Spasticity Baclofen (1st choice) Frequently high dosage required
Tizanidine (2nd
choice)
Good effect also against dyskinesia
Tetrahydrocannabinol “Add-on”medication, increase dosage slowly
up to 0.07 mg/kg/d,
Botulinum toxin Local application by injection to muscles;
always accompanied by physical therapy
a Avoid overtreatment, as most seizures in NCL are treatment-resistant.
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avoided (carbamazepine, gabapentin and lamotrigine in late infantile
NCL types). Reduction or rationalization of a patient's medication load
may sometimes improve myoclonus.
Spasticity, when it causes discomfort, should be treated with
physical therapy andmedication. Baclofen and tizandine are effective.
Tetrahydrocannabinol has also been used. Benzodiazepines may be
effective but have frequent side effects, lose their efﬁcacy with time,
and sometimes appear to have a negative effects on the general
disease course. Underlying painful events (see below) may trigger
terrifying spastic exacerbations and must be recognized.
Episodes of apparent or suspected pain are frequent and are caused
by a great variety of factors. Some of them are related to chronic immo-
bility such as pathological skeletal fractures, renal calculi, or venous
thrombosis. Abdominal pain may be caused by constipation due to
disease-related intestinal hypomotility or malnutrition. Recognition
and management of pain in NCL patients requires particular skills [29].
Diagnosis and treatment of tormenting psychopathological symp-
toms such as sleep disturbance, fear, aggressive behavior, depression,
and hallucinations represent a particular challenge. Careful and pains-
taking documentation of these symptoms, recognition of context and
possible triggers can be extremely helpful in managing environmental
exacerbating factors. Psychopharmacologic medication should be
given only after careful consideration and in consultation with child
neurologists and child psychiatrists, parents, and caregivers. Drugs to
consider for psychotic symptoms in juvenile NCL are risperidone for
hallucinations or panic attacks and ﬂuvoxamine for anxiety and
depression.Acknowledgements
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